Arbutus to Report Third Quarter 2020 Financial Results and Provide Corporate Update
October 29 2020 - 8:00AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company primarily focused on developing a cure
for people with chronic hepatitis B virus (HBV) infection, as well
as therapies to treat coronaviruses (including COVID-19), today
announced that it has scheduled its third quarter 2020 financial
results and corporate update for Thursday, November 5, 2020. The
schedule for the press release and conference call/webcast are as
follows:
• |
Q3 2020 Press Release: |
November 5, 2020 at 7:30 a.m. ET |
• |
Q3 2020 Conference Call/Webcast: |
November 5, 2020 at 8:45 a.m. ET |
• |
Domestic Dial-In Number: |
(866) 393-1607 |
• |
International Dial-In Number: |
(914) 495-8556 |
• |
Conference ID Number: |
7161816 |
A live webcast of the conference call can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com or directly at Live Webcast.
An archived webcast will be available on the
Arbutus website after the event. Alternatively, you may access a
replay of the conference call by calling (855) 859-2056 or (404)
537-3406, and reference conference ID: 7161816.
About Arbutus
Arbutus Biopharma Corporation is a publicly
traded (Nasdaq: ABUS) biopharmaceutical company dedicated to
discovering, developing and commercializing a cure for people with
chronic hepatitis B virus (HBV) infection. The Company is advancing
multiple drug product candidates that may be combined into a
potentially curative regimen for chronic HBV infection. Arbutus has
also initiated a drug discovery and development effort for treating
coronaviruses (including COVID-19). For more information, visit
www.arbutusbio.com.
Contact Information
Investors and Media
William H. CollierPresident and CEO Phone: 267-469-0914Email:
ir@arbutusbio.comPam MurphyInvestor Relations ConsultantPhone:
267-469-0914Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024